Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
星尘生物科技(上海)有限公司 logo — Pioneering affordable and swift cell therapy advancements fo...

星尘生物科技(上海)有限公司

Pioneering affordable and swift cell therapy advancements for enhanced tumor treatment outcomes across global regions.

Founded 2018 3 employees Venture round Total: $80.00M Biotechnology, Health Care

General Information

Company Name 星尘生物科技(上海)有限公司
Founded Year 2018
Employees 3
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with 星尘生物科技(上海)有限公司. To contact 星尘生物科技(上海)有限公司, visit triarmbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does 星尘生物科技(上海)有限公司 compare?

A PDF of 星尘生物科技(上海)有限公司 and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting 星尘生物科技(上海)有限公司 soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About 星尘生物科技(上海)有限公司

TriArm Therapeutics is a pioneering biotechnology startup, with a vision to advance affordable and swift cell therapy treatments for enhanced tumor therapy outcomes globally. Established in 2018 by Panacea Venture, the company has research and development centers in Germany, the United States, and the Greater China region. It focuses on the study and clinical application of CD19 CAR-T treatments using non-viral gene transfer methods, significantly reducing the expense and time required for cell therapy product preparation. This innovative approach is poised to lead to improved tumor therapy results. The latest funding round on 27 September 2021 amounted to a substantial $60.00M, with investments from EFung Capital, HongTao Capital, Panacea Venture, Viventures, and Junpu. With its cutting-edge research and strong investor backing, TriArm Therapeutics is well-positioned to make a significant impact in the biotechnology and healthcare industries.

Business keywords: Cell Therapy, Tumor Treatment, CD19 CAR-T, Non-viral Gene Transfer, Research and Development, Global Operations, Panacea Venture, Affordable Healthcare, Swift Advancements

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $60.00M 5
EFung Capital HongTao Capital Panacea Venture
EFung Capital, HongTao Capital +3
27 Sep 2021
Series A $20.00M 5
EFung Capital HongTao Capital Panacea Venture
EFung Capital, HongTao Capital +3
19 Jul 2019

星尘生物科技(上海)有限公司 Alternatives & Competitors

View All Alternatives
星尘生物科技(上海)有限公司 vs
Genenta Science (Nasdaq: GNTA)
Genenta Science (Nasdaq: GNTA) Italy

Genenta is a clinical stage immuno-oncology company

Post-IPO Secondary
25 employees
Biotechnology, Health Care
星尘生物科技(上海)有限公司 vs
Inceptor Bio
Inceptor Bio United States

Advancing Cell and Gene Therapies to Cure Cancer

Debt Financing
28 employees
Biotechnology, Health Care
星尘生物科技(上海)有限公司 vs
Interius BioTherapeutics
Interius BioTherapeutics United States

Interius is developing new ways to engineer cells inside the human body, right where they live

Acquired
16 employees
Biopharma, Biotechnology
View all alternatives

FAQ About 星尘生物科技(上海)有限公司

Pioneering affordable and swift cell therapy advancements for enhanced tumor treatment outcomes across global regions.
星尘生物科技(上海)有限公司 was founded in 2018.
星尘生物科技(上海)有限公司 operates in Biotechnology and Health Care. Its work centres on Cell Therapy, Tumor Treatment, CD19 CAR-T and Non-viral Gene Transfer.
星尘生物科技(上海)有限公司 has approximately 3 employees.
星尘生物科技(上海)有限公司 has completed 2 funding rounds, raising a total of $80.00M. The latest funding stage is Venture round.
Top alternatives and competitors to 星尘生物科技(上海)有限公司 include Genenta Science (Nasdaq: GNTA), Inceptor Bio, Interius BioTherapeutics, LumaCyte, Anocca. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
星尘生物科技(上海)有限公司 and Genenta Science (Nasdaq: GNTA) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for 星尘生物科技(上海)有限公司, https://bouncewatch.com/company/triarm-therapeutics, updated 21 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout